(MENAFN- EIN Presswire) EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

What Is The Expected Cagr For The Acute Ischemic Stroke Drugs Market Through 2025?
In recent times, the market for acute ischemic stroke drugs has seen consistent growth. It is set to expand from $13.5 billion in 2024 to $14.07 billion in 2025, boasting a compound annual growth rate (CAGR) of 4.3%. This growth pattern during the historic period is mainly due to factors such as the rising number of stroke cases, government schemes and health regulations, enhanced awareness and education, strategic collaborations and alliances, and an ageing population.

The market for acute ischemic stroke drugs is predicted to witness substantial expansion in the coming years, growing to ""$17.62 billion by 2029"" at a compound annual growth rate (CAGR) of 5.8%. This predicted growth during the forecast period is due to several key factors, including emerging therapies and drug advancements, precision and personalized treatments, the development of global healthcare infrastructure, increased healthcare spending, and the rise of telemedicine and remote patient monitoring. Foreseen trends during this period involve advancements in thrombolytic therapies, the development of neuroprotective agents, continued research in personalized medicine and biomarkers, telemedicine and remote surveillance, and collaborative efforts and strategic partnerships.

Download a free sample of the acute ischemic stroke drugs market report:

What Are The Driving Factors Impacting The Acute Ischemic Stroke Drugs Market?
The growing occurrence of chronic conditions is expected to fuel the expansion of the acute ischemic stroke drug market in the near future. Chronic diseases, also referred to as non-communicable ailments, are those that last a year or more, necessitating sustained medical intervention and potentially interrupting daily activities. The foremost sources of death and disability are chronic conditions like heart ailments, cancer, and diabetes. Acute ischemic stroke medicines are predominantly employed in treating these conditions to mitigate the risk of clotting and strokes, and reestablish cerebral blood flow. As an example, the World Health Organization (WHO), a health organization based in Switzerland, reported in September 2022 that chronic diseases are responsible for around 41 million deaths annually, equating to 74% of total global deaths. Furthermore, around 17 million people die prematurely, before reaching 70, due to chronic diseases. By 2025, it is projected that nearly 164 million Americans, nearly half the population, will be afflicted with chronic diseases. For these reasons, the increasing occurrence of chronic diseases is propelling the expansion of the acute ischemic stroke drug market.

Which Players Dominate The Acute Ischemic Stroke Drugs Industry Landscape?
Major players in the Acute Ischemic Stroke Drugs include:
. F. Hoffmann-La Roche AG
. C.H. Boehringer Sohn AG & Co. KG
. Bristol-Myers Squibb Company
. Daiichi Sankyo Company Limited
. AstraZeneca plc
. ZZ Biotech LLC
. NoNO Inc.
. Biogen Inc.
. Athersys Inc.
. Bayer AG

What Are The Future Trends Of The Acute Ischemic Stroke Drugs Market?
Leading firms in the acute ischemic stroke drug market are making strides in creating innovative medicines, including sublingual formulations of edaravone and dexborneol for acute ischemic stroke. The sublingual edaravone and dexborneol formulation, designed for rapid absorption into the bloodstream when placed under the tongue, leverages the antioxidant and anti-inflammatory properties of both components to boost treatment effectiveness. For example, breakthrough therapy designation was granted to Sanbexin, a sublingual formulation of edaravone and dexborneol, by China's Simcere Pharmaceutical in October 2024 for AIS treatment. The decision was based on encouraging results from the TASTE-SL phase 3 clinical trial (NCT04950920), which showed 64.4% of patients treated with Sanbexin attained a modified Rankin Scale (mRS) score of ≤1 at 90 days, compared to the 54.7% in the placebo group. This treatment, which can be applied outside hospital environments, is designed to decrease disability and enhance outcomes in patients with AIS.

Global Acute Ischemic Stroke Drugs Market Segmentation By Type, Application, And Region
The acute ischemic stroke drugs market covered in this report is segmented –
1) By Type: Tablet, Capsule, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Hospitals, Diagnostic Centers, Other Applications

Subsegments:
1) By Tablet: Immediate Release Tablets, Extended Release Tablets, Orally Disintegrating Tablets
2) By Capsule: Hard Shell Capsules, Soft Gelatin Capsules, Extended Release Capsules
3) By Other Types: Injectable Solutions, Intravenous (IV) Preparations, Inhalation Formulations

View the full acute ischemic stroke drugs market report:

Which Region Holds The Largest Market Share In The Acute Ischemic Stroke Drugs Market?
In 2024, North America stood as the dominant region in the acute ischemic stroke drugs market. The Asia-Pacific region, on the other hand, is predicted to experience the most rapid growth during the forecast period. The report on the acute ischemic stroke drugs market encompasses regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Acute Ischemic Stroke Drugs Market 2025, By The Business Research Company

Data Protection As A Service Global Market Report 2025
/report/data-protection-as-a-service-global-market-report

Cloud Security Global Market Report 2025
/report/cloud-security-global-market-report

Application Security Global Market Report 2025
/report/application-security-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email:...
The Business Research Company -

Follow Us On:
. LinkedIn: "

MENAFN23112025003118003196ID1110386211